First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).

被引：36
|
作者：
Alsina, Maria
Boni, Valentina
Schellens, Jan H. M.
Moreno, Victor
Bol, Kees
Westendorp, Martine
Sirulnik, L. Andres
Tabernero, Josep
Calvo, Emiliano
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
[2] START Madrid CIOCC, Hosp HM Univ Sanchinarro, Madrid, Spain
[3] Netherlands Canc Inst, Amsterdam, Netherlands
[4] Start Madrid FJD, Hosp Fdn, Madrid, Spain
[5] Merus NV, Utrecht, Netherlands
[6] Vall Hebron Univ Hosp, Inst Oncol VHIO, Barcelona, Spain
[7] START Madrid, Centro Integral Oncol Clara Campal, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2522
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Marcia R. Campbell
    Hui Zhang
    Shabnam Ziaee
    Ana Ruiz-Saenz
    Nathaniel Gulizia
    Julie Oeffinger
    Dhara N. Amin
    Deepika Ahuja
    Mark M. Moasser
    Catherine C. Park
    Breast Cancer Research and Treatment, 2016, 155 : 431 - 440
  • [32] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Sarina A. Piha-Paul
    Analía Azaro
    Hendrik Tobias Arkenau
    Do-Youn Oh
    Matthew D. Galsky
    Sumanta Kumar Pal
    Kensuke Hamada
    Yaohua He
    Ikuo Yamamiya
    Karim A Benhadji
    Antoine Hollebecque
    Investigational New Drugs, 2021, 39 : 1324 - 1334
  • [33] Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
    Campbell, Marcia R.
    Zhang, Hui
    Ziaee, Shabnam
    Ruiz-Saenz, Ana
    Gulizia, Nathaniel
    Oeffinger, Julie
    Amin, Dhara N.
    Ahuja, Deepika
    Moasser, Mark M.
    Park, Catherine C.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 431 - 440
  • [34] A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
    Lathrop, K.
    Lucas, J.
    Vacirca, J. L.
    Bhat, G.
    Choi, M. R.
    Naughton, M.
    CANCER RESEARCH, 2017, 77
  • [35] BIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Kudla, A.
    Adiwijaya, B.
    Paragas, V.
    Richards, D.
    Braiteh, F.
    Garcia, A. A.
    Denlinger, C. S.
    Conkling, P.
    Edenfield, W. J.
    Anthony, S.
    Hellerstedt, B.
    Raju, R.
    Becerra, C.
    Harb, W.
    Smith, D.
    Kawash, K.
    Frye, S.
    McDonagh, C. F.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2014, 25
  • [36] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Piha-Paul, Sarina A.
    Azaro, Analia
    Arkenau, Hendrik Tobias
    Oh, Do-Youn
    Galsky, Matthew D.
    Pal, Sumanta Kumar
    Hamada, Kensuke
    He, Yaohua
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hollebecque, Antoine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1324 - 1334
  • [37] Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+metastatic breast cancer (MBC)
    Carraro, S.
    Campos, D.
    Copigneaux, C.
    Saintilien, C.
    Beckman, R. A.
    Korbenfeld, E.
    Coppola, M. P.
    Halabe, K.
    Cazap, E.
    CANCER RESEARCH, 2013, 73
  • [38] A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
    Pullarkat, V
    Deo, Y
    Link, J
    Spears, L
    Marty, V
    Curnow, R
    Groshen, S
    Gee, C
    Weber, JS
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 48 (01) : 9 - 21
  • [39] A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu
    V. Pullarkat
    Y. Deo
    J. Link
    L. Spears
    V. Marty
    R. Curnow
    S. Groshen
    C. Gee
    J. S. Weber
    Cancer Immunology, Immunotherapy, 1999, 48 : 9 - 21
  • [40] Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)
    Overmoyer, B.
    Regan, M.
    Schlosnagle, E.
    Bunnell, C.
    Freedman, R.
    Tolaney, S.
    Chen, W.
    Mayer, E.
    Partridge, A.
    Silver, D.
    Winer, E.
    CANCER RESEARCH, 2017, 77
12345